Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients
| Autor: | Asbjørn Svardal, Rolf K. Berge, Dagfinn Ekse, Bjørn Netteland, Dag Clement Johannessen, Per Eystein Lønning, Hildegunn Berntsen |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Breast Neoplasms Toxicology Formestane Dexamethasone chemistry.chemical_compound Exemestane Internal medicine Blood plasma medicine Humans Pharmacology (medical) Enzyme Inhibitors Aromatase Aged Pharmacology Aromatase inhibitor biology Aromatase Inhibitors Chemistry gamma-Glutamyltransferase Glutathione Middle Aged Aminoglutethimide Endocrinology Oncology biology.protein Female medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 42:46-52 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s002800050783 |
| Popis: | Purpose: Elevated cellular glutathione has been associated with resistance to cancer chemotherapy. Treatment with the aromatase inhibitor aminoglutethimide increases the concentration of γ-glutamyl transpeptidase (γ-GT) in breast cancer patients. This enzyme catalyzes the first step in the degradation of extracellular glutathione, and the products formed may act as precursors for intracellular glutathione synthesis. Methods: Plasma and red-blood-cell glutathione levels were determined in 26 patients suffering from advanced breast cancer before and during treatment with aminoglutethimide (n=16) or the steroidal aromatase inhibitors exemestane or formestane (n=10) and in 5 cancer patients receiving dexamethasone. Results: Pretreatment values for γ-GT in the total patient group (n=31) correlated negatively with the level of reduced (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink